This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Gaining Insight into the 52-Week Data Readout of Nektar Therapeutics’ Rezpegaldesleukin in Atopic Dermatitis
Ticker(s): NKTRWho's the expert?
Institution: Yale
- Associate Professor of Dermatology Yale School of Medicine
- Currently manages 120 patients with atopic dermatitis and 60 with vitiligo.
- Pioneered the use of JAK Inhibitors in cutaneous diseases and has published extensively on their use in atopic dermatitis, vitiligo and alopecia areata, among other dermatologic diseases.
Interview GoalTo gain a deeper understanding of Nektar Therapeutics’ Rezpegaldesleukin as a potential treatment in atopic dermatitis
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
